These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 25039933)

  • 61. Hemovigilance in Massachusetts and the adoption of statewide hospital blood bank reporting using the National Healthcare Safety Network.
    Cumming M; Osinski A; O'Hearn L; Waksmonski P; Herman M; Gordon D; Griffiths E; Knox K; McHale E; Quillen K; Rios J; Pisciotto P; Uhl L; DeMaria A; Andrzejewski C
    Transfusion; 2017 Feb; 57(2):478-483. PubMed ID: 27774608
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Main principles of effective hemotherapy].
    Dobrý E
    Cas Lek Cesk; 1968 Nov; 107(47):1436-8. PubMed ID: 5696569
    [No Abstract]   [Full Text] [Related]  

  • 63. Physiologic considerations in the management of hemophilia.
    Briggs DK
    Pathobiol Annu; 1971; 1():205-14. PubMed ID: 4950380
    [No Abstract]   [Full Text] [Related]  

  • 64. 7th International Association of Biological Standardization (IABS) Symposium on Advances in Transfusion Safety.
    Teo D
    Biologicals; 2012 May; 40(3):169. PubMed ID: 22507451
    [No Abstract]   [Full Text] [Related]  

  • 65. A framework for applying the precautionary principle to transfusion safety.
    Wilson K
    Transfus Med Rev; 2011 Jul; 25(3):177-83. PubMed ID: 21429704
    [TBL] [Abstract][Full Text] [Related]  

  • 66. ISBT Board response to the Dublin consensus statement.
    Flanagan P
    Vox Sang; 2011 Feb; 100(2):250-1. PubMed ID: 20946536
    [No Abstract]   [Full Text] [Related]  

  • 67. [Management by objectives: an experience by transfusion and immunology service in Rabat].
    Essakalli M; Atouf O; Ouadghiri S; Bouayad A; Drissi A; Sbain K; Sakri L; Benseffaj N; Brick C
    Transfus Clin Biol; 2013 Sep; 20(4):440-7. PubMed ID: 23871462
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Haemophilia treatment: where to from here? Have the risks increased?
    Faed J
    N Z Med J; 2003 Aug; 116(1180):U559. PubMed ID: 14581981
    [No Abstract]   [Full Text] [Related]  

  • 69. Domestic and imported products--the Malaysian experience in assuring safe and sufficient plasma products.
    Ayob Y
    Dev Biol (Basel); 2007; 127():169-73. PubMed ID: 17486890
    [No Abstract]   [Full Text] [Related]  

  • 70. Ten years of transfusion practitioners and better blood transfusion in Scotland.
    Dalrymple K; Watson D
    Nurs Manag (Harrow); 2014 Mar; 20(10):27-30. PubMed ID: 24571162
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Safer haemotherapy: the responsibilities of government, transfusion service, blood donors, and physician-users.
    Moore BP
    Haematologia (Budap); 1995; 27(1):39-45. PubMed ID: 12051295
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Pharmacoeconomic impact of obesity in severe haemophilia children on clotting factor prophylaxis in a single institution.
    Majumdar S; Ostrenga A; Latzman RD; Payne C; Hunt Q; Morris A; Iyer R
    Haemophilia; 2011 Jul; 17(4):717-8. PubMed ID: 21323798
    [No Abstract]   [Full Text] [Related]  

  • 73. [Current status of hemophilia treatment].
    Veltkamp JJ
    Ned Tijdschr Geneeskd; 1979 Dec; 123(49):2108-9. PubMed ID: 522912
    [No Abstract]   [Full Text] [Related]  

  • 74. International challenges of self-sufficiency in blood products.
    Dhingra N
    Transfus Clin Biol; 2013 May; 20(2):148-52. PubMed ID: 23643329
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Securing better, safer blood supplies in Latin America.
    Lancet; 2014 Oct; 384(9951):1322. PubMed ID: 25307832
    [No Abstract]   [Full Text] [Related]  

  • 76. Improving processes for blood factor products: from blood bank to hospital pharmacy.
    Summa MA; Culligan MW; Nabors P
    Am J Health Syst Pharm; 2010 Feb; 67(4):265-7. PubMed ID: 20133529
    [No Abstract]   [Full Text] [Related]  

  • 77. Drug therapy reviews: clinical use of hemostatic agents.
    Lowe GD; Lawson DH
    Am J Hosp Pharm; 1978 Apr; 35(4):414-22. PubMed ID: 306196
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Leukocyte depletion of blood products: a requirement for improvement of quality and safety].
    De Pauw BE; Van den Bos A
    Ned Tijdschr Geneeskd; 2000 Sep; 144(36):1754-6. PubMed ID: 10992905
    [No Abstract]   [Full Text] [Related]  

  • 79. Theme section: safety challenges in transfusion practices.
    Seghatchian J
    Transfus Apher Sci; 2008 Oct; 39(2):137-8. PubMed ID: 18706864
    [No Abstract]   [Full Text] [Related]  

  • 80. What is plaguing blood banking: shortage of blood or ignorance of doctors?
    Shivaram C
    Natl Med J India; 2000; 13(2):107-8. PubMed ID: 10835865
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.